Cantor Fitzgerald Reiterates “$140.00” Price Target for AnaptysBio (ANAB)

AnaptysBio (NASDAQ:ANAB) has been assigned a $140.00 price target by Cantor Fitzgerald in a research note issued on Friday. The firm presently has a “buy” rating on the biotechnology company’s stock. Cantor Fitzgerald’s price objective would indicate a potential upside of 92.47% from the stock’s previous close.

ANAB has been the topic of several other reports. Royal Bank of Canada reiterated a “hold” rating and set a $84.00 price objective on shares of AnaptysBio in a research report on Wednesday, August 8th. Jefferies Financial Group reiterated a “buy” rating and set a $121.00 price objective on shares of AnaptysBio in a research report on Tuesday, August 7th. Credit Suisse Group set a $147.00 price objective on AnaptysBio and gave the company a “buy” rating in a research report on Thursday, September 27th. Zacks Investment Research upgraded AnaptysBio from a “hold” rating to a “buy” rating and set a $93.00 price objective on the stock in a research report on Monday, August 13th. Finally, Wedbush reiterated an “outperform” rating and set a $138.00 price objective on shares of AnaptysBio in a research report on Tuesday, September 18th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have assigned a buy rating to the company’s stock. AnaptysBio presently has a consensus rating of “Buy” and an average target price of $130.50.

NASDAQ ANAB traded down $8.30 during trading on Friday, reaching $72.74. The company’s stock had a trading volume of 629,257 shares, compared to its average volume of 317,514. The firm has a market capitalization of $1.93 billion, a P/E ratio of -47.86 and a beta of 3.47. The company has a quick ratio of 16.19, a current ratio of 16.19 and a debt-to-equity ratio of 0.01. AnaptysBio has a one year low of $64.72 and a one year high of $134.00.

AnaptysBio (NASDAQ:ANAB) last announced its earnings results on Thursday, November 8th. The biotechnology company reported ($0.66) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.71) by $0.05. The business had revenue of $5.00 million during the quarter. As a group, research analysts anticipate that AnaptysBio will post -2.72 EPS for the current fiscal year.

Several institutional investors have recently made changes to their positions in the company. Janus Henderson Group PLC boosted its holdings in AnaptysBio by 11.1% during the 3rd quarter. Janus Henderson Group PLC now owns 3,143,155 shares of the biotechnology company’s stock valued at $313,592,000 after acquiring an additional 312,833 shares during the period. BlackRock Inc. boosted its holdings in AnaptysBio by 2.9% during the 2nd quarter. BlackRock Inc. now owns 1,464,624 shares of the biotechnology company’s stock valued at $104,046,000 after acquiring an additional 41,507 shares during the period. OppenheimerFunds Inc. boosted its holdings in AnaptysBio by 5.2% during the 2nd quarter. OppenheimerFunds Inc. now owns 1,101,887 shares of the biotechnology company’s stock valued at $78,278,000 after acquiring an additional 54,773 shares during the period. Federated Investors Inc. PA boosted its holdings in AnaptysBio by 11.4% during the 2nd quarter. Federated Investors Inc. PA now owns 491,400 shares of the biotechnology company’s stock valued at $34,909,000 after acquiring an additional 50,170 shares during the period. Finally, Wells Fargo & Company MN boosted its holdings in AnaptysBio by 717.6% during the 3rd quarter. Wells Fargo & Company MN now owns 299,740 shares of the biotechnology company’s stock valued at $29,904,000 after acquiring an additional 263,078 shares during the period.

About AnaptysBio

AnaptysBio, Inc, a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company's proprietary anti-inflammatory pipeline includes ANB020, an anti-interleukin-33 antibody for the treatment of moderate-to-severe adult atopic dermatitis, severe adult peanut allergy, and severe adult eosinophilic asthma; ANB019, an anti-interleukin-36R antibody for the treatment of rare inflammatory diseases, including generalized pustular psoriasis and palmo-plantar pustular psoriasis; and a portfolio of checkpoint receptor agonist antibodies for the treatment of certain autoimmune diseases.

Recommended Story: How dollar cost averaging works

Analyst Recommendations for AnaptysBio (NASDAQ:ANAB)

Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply